Non-muscle-invasive bladder cancer (NMIBC) is the most common neoplasm of the urinary tract and requires life-long invasive surveillance to detect disease recurrence. Currently, there are no effective oral therapies that delay disease recurrence or progression. We...
Eugen will support the expansion of Clinerion’s Patient Network Explorer to hospitals and clinical trial sites in Uruguay. Eugen will also offer Patient Network Explorer services on behalf of Clinerion to clinical researchers and trial sponsors in Uruguay. MONTEVIDEO,...
IMVT-1401, a fully human anti-FcRn antibody designed to be administered via subcutaneous injection, is the only anti-FcRn antibody known to be in clinical development for the treatment of GO Topline results from the ASCEND-GO 2 program are expected in early 2021...
Safety and efficacy evaluation will be performed on 36 patients from 3 hospitals located in US and Australia While bevacizumabparticularly blocks the signaling activated by VEGF-A, Olinvacimab manages to block the signaling activated by VEGF-A, C, and D. PharmAbcine,...
BOSTON and CARLSBAD, Calif., Nov. 25, 2019 — Akcea Therapeutics Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced initiation of the NEURO-TTRansform Phase 3 clinical...
HOUSTON, Nov. 26, 2019 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announces...
Email
Text